Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid sales

  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 24 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 97%

Ireland News News

Ireland Ireland Latest News,Ireland Ireland Headlines

Shares of Bristol Myers Squibb Co. shed 2.2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its...

Shares of Bristol Myers Squibb Co. BMY shed 2.2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its full-year outlook, amid a more rapid than expected decline in sales of its cancer treatment Revlimid. Net income rose to $2.07 billion, or 99 cents a share, from $1.42 billion, or 66 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $1.75 missed the FactSet consensus of $1.98. Revenue fell 5.

2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its full-year outlook, amid a more rapid than expected decline in sales of its cancer treatment Revlimid. Net income rose to $2.07 billion, or 99 cents a share, from $1.42 billion, or 66 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earnings per share of $1.75 missed the FactSet consensus of $1.98. Revenue fell 5.6% to $11.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 3. in İE
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Ireland Ireland Latest News, Ireland Ireland Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Alphabet stock jumps on earnings while Microsoft shares dip, and other stocks on the moveAlphabet, Microsoft, Dish Networks and PacWest Bancorp are among the stocks in the spotlight.
Source: MarketWatch - 🏆 3. / 97 Read more »